Clinical outcome of prophylactic oophorectomy in BRCA1/BRCA2 mutation carriers and events during follow-up

por Olivier, R I, van Beurden, M, Lubsen, M A C, Rookus, M A, Mooij, T M, van de Vijver, M J, van't Veer, L J
Publicado 2004

Risk reduction of contralateral breast cancer and survival after contralateral prophylactic mastectomy in BRCA1 or BRCA2 mutation carriers

por van Sprundel, T C, Schmidt, M K, Rookus, M A, Brohet, R, van Asperen, C J, Rutgers, E J Th, van‘t Veer, L J, Tollenaar, R A E M
Publicado 2005

No efficacy of annual gynaecological screening in BRCA1/2 mutation carriers; an observational follow-up study

por Hermsen, B B J, Olivier, R I, Verheijen, R H M, van Beurden, M, de Hullu, J A, Massuger, L F, Burger, C W, Brekelmans, C T, Mourits, M J, de Bock, G H, Gaarenstroom, K N, van Boven, H H, Mooij, T M, Rookus, M A
Publicado 2007

Timing of risk reducing mastectomy in breast cancer patients carrying a BRCA1/2 mutation: retrospective data from the Dutch HEBON study

por Wevers, M. R., Schmidt, M. K., Engelhardt, E. G., Verhoef, S., Hooning, M. J., Kriege, M., Seynaeve, C., Collée, M., van Asperen, C. J., Tollenaar, R. A. E. M., Koppert, L. B., Witkamp, A. J., Rutgers, E. J. T., Aaronson, N. K., Rookus, M. A., Ausems, M. G. E. M.
Publicado 2015

Characteristics of small breast and/or ovarian cancer families with germline mutations in BRCA1 and BRCA2

por Ligtenberg, M J L, Hogervorst, F B L, Willems, H W, Arts, P J W, Brink, G, Hageman, S, Bosgoed, E A J, Looij, E Van der, Rookus, M A, Devilee, P, Vos, E M A W, Wigbout, G, Struycken, P M, Menko, F H, Rutgers, E J Th, Hoefsloot, E H, Mariman, E C M, Brunner, H G, Veer, L J Van't
Publicado 1999